NCT02303860

Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)

Pharmacokinetic Study of ORM-12741 After Multiple Oral Doses

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Orion Corporation, Orion Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate ORM-12741 concentrations in blood at steady state.

Detailed description

The purpose of this study is to evaluate pharmacokinetic and safety of ORM-12741 after multiple oral dosing of modified release formulations.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ORM-12741 MR A	Modified release formulation of ORM-12741
DRUG	ORM-12741 MR B	Modified release formulation of ORM-12741
DRUG	ORM-12741 IR	Immediately release formulation of ORM-12741

Timeline

• Start date: 2014-10-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2014-12-01
• Last updated: 2015-05-06

Locations

1 site across 1 country: Finland